Adults who drink just one sugar-sweetened beverage a day face roughly 60 percent higher odds of developing non-alcoholic fatty liver disease compared with people who skip those drinks entirely. That finding, drawn from cross-sectional data in the Framingham Heart Study cohorts, has since been reinforced by a separate dose-response meta-analysis and by large European and UK Biobank studies that extend the pattern to artificially sweetened drinks as well. With NAFLD rates climbing worldwide and sweetened beverages still a daily habit for millions, the accumulating evidence puts a specific number on a risk that many drinkers may not associate with liver health at all.
Why a single daily soda carries measurable liver risk
The core statistic is striking in its precision. Researchers analyzing the Framingham Heart Study cohorts found an adjusted odds ratio of approximately 1.61 for fatty liver disease among adults consuming at least one sugar-sweetened serving per day versus non-consumers, as reported in a detailed Framingham analysis. That ratio held after adjustments for age, sex, smoking, physical activity, and other dietary factors, which means the association was not simply a proxy for an overall unhealthy diet or higher calorie intake.
A broader systematic review and meta-analysis of observational studies confirmed that the relationship between sugar-sweetened beverages and NAFLD follows a dose-dependent pattern, with risk rising as daily intake increased, according to a large dose–response review. The consistency across study designs and populations makes it harder to dismiss the link as a statistical artifact confined to one cohort or one country.
The mechanism behind this association likely involves fructose metabolism. When the liver processes large amounts of fructose, found in high concentrations in sodas and fruit-flavored drinks, it converts the sugar directly into fat through a process called de novo lipogenesis. Over months and years, that fat accumulates in liver cells, eventually producing the condition clinicians diagnose as NAFLD. Because the liver handles fructose differently from glucose, the organ bears a disproportionate metabolic burden from sweetened drinks even when total calorie intake stays moderate.
Liquid calories also bypass some of the body’s natural satiety checks. People tend not to reduce food intake enough to compensate for the extra energy from a daily soda or sweetened tea. That combination-rapid fructose delivery to the liver and incomplete calorie compensation-creates a biochemical environment that favors fat buildup and low-grade inflammation in hepatic tissue.
Framingham, European cohorts, and UK Biobank data point the same direction
What makes the current body of evidence unusually persuasive is that independent research teams, using different populations and different diagnostic tools, have reached compatible conclusions. The Framingham analysis relied on imaging-confirmed fatty liver in a well-characterized U.S. cohort. The SWEET project, a multi-cohort European analysis that used the Fatty Liver Index with a threshold of 60 or above as a standardized proxy for NAFLD, reported that each additional daily serving of sugar-sweetened beverages was associated with higher disease prevalence, as described in a large European cohort study. That work also examined low-calorie and no-calorie beverages, adding a comparative dimension that single-beverage analyses lack.
The UK Biobank has contributed two related lines of investigation. One study examined sugar-sweetened beverages, artificially sweetened beverages, and pure fruit juice in relation to NAFLD using both cross-sectional and longitudinal designs, according to the UK Biobank’s own publication record. A separate analysis applied Cox regression to proteomic data from the same cohort and found that proteomic signatures tied to sweetened beverage consumption were associated with higher risk of adverse liver outcomes, again based on internal Biobank reporting.
That proteomic work introduces a biological layer that goes beyond simple dietary questionnaires. If specific protein patterns in the blood shift measurably in response to sweetened drink consumption, and those same patterns predict liver disease years later, then researchers have a potential causal pathway rather than just a statistical correlation. The hypothesis that proteomic shifts triggered by daily sugar-sweetened beverage intake mediate a substantial share of the observed NAFLD risk elevation, independent of total energy intake and body mass index, is consistent with the available data but has not yet been confirmed through formal mediation analysis with publicly released coefficients.
Findings presented at UEG Week 2025, based on additional UK Biobank data, added another dimension by linking both artificially sweetened and sugary drinks to increased liver disease risk. That conference presentation suggests the problem may not be limited to sugar alone, raising questions about whether artificial sweeteners affect liver metabolism through different but overlapping pathways. Although those results are preliminary and await full peer-reviewed publication, they align with the broader pattern that frequent consumption of sweet-tasting beverages-regardless of the specific sweetener-tracks with higher odds of fatty liver.
Gaps in the data and what to watch next
Several important questions remain open. The Framingham study and the European SWEET project are observational, meaning they can identify associations but cannot prove that sugary drinks directly cause NAFLD in every individual. Confounding factors such as unmeasured aspects of diet, socioeconomic status, or genetic susceptibility could still influence the results, even after extensive statistical adjustment. The UK Biobank analyses, while larger and more detailed, face similar limitations because participants are not randomly assigned to beverage patterns.
Randomized controlled trials would offer stronger evidence, but long-term experiments that deliberately expose people to potentially harmful beverage regimens raise ethical and practical barriers. Shorter trials have shown that high-fructose drinks can increase liver fat and triglycerides over weeks to months, yet they cannot fully capture the decade-long trajectories that lead to clinically significant NAFLD, cirrhosis, or liver cancer. Bridging that gap between short-term metabolic changes and long-term disease will require creative study designs that combine trial data, observational cohorts, and mechanistic modeling.
Another uncertainty involves dose thresholds. The existing data indicate that risk rises with each additional serving, but they do not define a universally “safe” level of intake. For some people, occasional consumption may carry minimal incremental risk, while others-particularly those with obesity, type 2 diabetes, or strong family histories of liver disease-could be more vulnerable even at modest intake levels. Genetic variants that influence fructose metabolism and insulin sensitivity may help explain these differences, yet they have not been fully integrated into current beverage–liver analyses.
The emerging signals around artificially sweetened beverages also call for caution. If future peer-reviewed studies confirm that diet sodas and other low-calorie drinks independently predict NAFLD, researchers will need to disentangle whether the risk reflects direct effects of sweeteners, changes in the gut microbiome, compensatory eating behaviors, or reverse causation (for example, people at higher metabolic risk switching to diet drinks). Until those mechanisms are clarified, clinicians may hesitate to recommend artificially sweetened beverages as a straightforwardly safer alternative for liver health.
What the evidence means for everyday choices
Despite the remaining gaps, the convergence of cohort data, meta-analyses, and mechanistic insights supports a cautious, pragmatic message: regular intake of sugar-sweetened beverages, even at just one serving per day, is linked to substantially higher odds of NAFLD, and similar patterns may extend to some artificially sweetened drinks. For individuals already concerned about liver health, reducing or eliminating sweetened beverages is a change with relatively low downside and potentially meaningful long-term benefit.
In practice, that can mean reserving sugary drinks for occasional use rather than daily habits, choosing water, unsweetened tea, or coffee as default options, and reading labels carefully on flavored waters and juices that may contain added sugars or intense sweeteners. For clinicians, the growing evidence base justifies asking routine questions about beverage intake when assessing liver risk, alongside more familiar factors like alcohol use and body weight.
On a population level, the findings may inform policy debates over soda taxes, warning labels, and marketing restrictions, especially in countries where NAFLD prevalence is rising fastest. While no single intervention will reverse the global burden of fatty liver disease, curbing the routine consumption of sweetened beverages-backed by clear communication of the kind of risk estimates now emerging from Framingham, European cohorts, and UK Biobank-offers a concrete, evidence-aligned starting point.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
